Comparison of Wild Type DNA Sequence of Spike Protein from SARS-CoV-2 with Optimized Sequence on The Induction of Protective Responses Against SARS-Cov-2 Challenge in Mouse Model

References

• Amanat F, Krammer F. SARS-CoV-2 Vaccines: status report. Immunity. 2020;52(4):583. doi:10.1016/j.immuni.2020.03.007.
   PubMed Web of Science ®Google Scholar
• Sakamoto A, Kawakami R, Kawai K, Gianatti A, Pellegrini D, Kutys R, Guo L, Mori M, Cornelissen A, Sato Y, et al. ACE2 (Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Serine Protease 2) expression and localization of SARS-CoV-2 infection in the human heart. Arterioscler Thromb Vasc Biol. 2020. doi:10.1161/ATVBAHA.120.315229.
   Google Scholar
• Huang WC, Zhou S, He X, Chiem K, Mabrouk MT, Nissly RH, Bird IM, Strauss M, Sambhara S, Ortega J, et al. SARS‐CoV‐2 RBD neutralizing antibody induction is enhanced by particulate vaccination. Adv Mater. 2020;32:2005637. doi:10.1002/adma.202005637.
   PubMed Web of Science ®Google Scholar
• Berger I, Schaffitzel C. The SARS-CoV-2 spike protein: balancing stability and infectivity. Cell Res. 2020;30:1059. doi:10.1038/s41422-020-00430-4.
   PubMed Web of Science ®Google Scholar
• Alarcon JB, Waine GW, McManus DP. DNA vaccines: technology and application as anti-parasite and anti-microbial agents. Adv Parasitol. 1999;42:343. doi:10.1016/s0065-308x(08)60152-9.
   PubMed Web of Science ®Google Scholar
• Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer. 2008;8:108. doi:10.1038/nrc2326.
   PubMed Web of Science ®Google Scholar
• Robinson HL, Pertmer TM. DNA vaccines for viral infections: basic studies and applications. Adv Virus Res. 2000;55:1. doi:10.1016/s0065-3527(00)55001-5.
   PubMed Web of Science ®Google Scholar
• Tebas P, Roberts CC, Muthumani K, Reuschel EL, Kudchodkar SB, Zaidi FI, White S, Khan AS, Racine T, Choi H, et al. Safety and immunogenicity of an Anti-Zika virus DNA vaccine - preliminary report. N Engl J Med. 2017. doi:10.1056/NEJMoa1708120.
   Web of Science ®Google Scholar
• Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh M-d, et al. Safety and immunogenicity of an anti-middle east respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 2019;19:1013. doi:10.1016/S1473-3099(19)30266-X.
   PubMed Web of Science ®Google Scholar
• Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, Wise M, Patel A, Izmirly A, Aljuaid A, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against middle east respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med. 2015;7(301):132. doi:10.1126/scitranslmed.aac7462.
   Web of Science ®Google Scholar
• Yang Z-Y, Kong W-P, Huang Y, Roberts A, Murphy BR, Subbarao K, Nabel GJ. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 2004;428(6982):561. doi:10.1038/nature02463.
   PubMed Web of Science ®Google Scholar
• Momin T, Kansagra K, Patel H, Sharma S, Sharma B, Patel J, Mittal R, Sanmukhani J, Maithal K, Dey A, et al. Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India. EClinicalMedicine. 2021;38:101020. doi:10.1016/j.eclinm.2021.101020.
   PubMedGoogle Scholar
• Smith T, Patel A, Ramos S, Elwood D, Zhu X, Yan J, Gary EN, Walker SN, Schultheis K, Purwar M, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020;11(1):2601. doi:10.1038/s41467-020-16505-0.
   PubMed Web of Science ®Google Scholar
• Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, Wei Q, Yu P, Xu Y, Qi F, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020;583(7818):830. doi:10.1038/s41586-020-2312-y.
   PubMed Web of Science ®Google Scholar
• Rydyznski MC, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, Belanger S, Abbott RK, Kim C, Choi J, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996. doi:10.1016/j.cell.2020.09.038.
   PubMed Web of Science ®Google Scholar
• Dispinseri S, Secchi M, Pirillo MF, TMSolazzi M, Borghi M, Brigatti C, De Angelis ML, Baratella M, Bazzigaluppi E, Venturi G, et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat Commun. 2021;12(1):2670. doi:10.1038/s41467-021-22958-8.
   PubMed Web of Science ®Google Scholar
• Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang M-L, Jerome KR, Bloom JD, Greninger AL. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J Clin Microbiol. 2020;58(11). doi:10.1128/JCM.02107-20.
   PubMedGoogle Scholar
• Wan J, Xing S, Ding L, Wang Y, Gu C, Wu Y, Rong B, Li C, Wang S, Chen K, et al. Human-IgG-neutralizing monoclonal antibodies block the SARS-CoV-2 infection. Cell Rep. 2020;32(3):107918. doi:10.1016/j.celrep.2020.107918.
   PubMed Web of Science ®Google Scholar
• Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, Wiethoff CM, Blackbourne JL, Heinz BA, Foster D, et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med. 2021;13(593):f1906. doi:10.1126/scitranslmed.abf1906.
   Web of Science ®Google Scholar
• Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature (London). 2020;584(7819):120. doi:10.1038/s41586-020-2381-y.
   PubMed Web of Science ®Google Scholar
• Wen J, Elong Ngono A, Regla-Nava JA, Kim K, Gorman MJ, Diamond, Shresta S. Dengue virus-reactive CD8(+) T cells mediate cross-protection against subsequent Zika virus challenge. Nat Commun. 2017;8(1):1459. doi:10.1038/s41467-017-01669-z.
   PubMedGoogle Scholar
• Hassert M, Harris MG, Brien JD, Pinto AK. Identification of protective CD8 T cell responses in a mouse model of Zika virus infection. Front Immunol. 2019;10:1678. doi:10.3389/fimmu.2019.01678.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Heslop HE. T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood. 2016;127(26):3331. doi:10.1182/blood-2016-01-628982.
   PubMed Web of Science ®Google Scholar
• Kolls JK. CD4+T-cell subsets and host defense in the lung. Immunol Rev. 2013;252(1):156. doi:10.1111/imr.12030.
   PubMedGoogle Scholar
• Larena M, Regner M, Lee E, Lobigs M. Pivotal role of antibody and subsidiary contribution of CD8+ T cells to recovery from infection in a murine model of Japanese Encephalitis. J Virol. 2011;85(11):5446. doi:10.1128/JVI.02611-10.
   PubMed Web of Science ®Google Scholar
• Prestwood TR, Morar MM, Zellweger RM, Miller R, May MM, Yauch LE, Lada SM, Shresta S. Gamma interferon (IFN-gamma) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-alpha/beta receptor-deficient mice. J Virol. 2012;86(23):12561. doi:10.1128/JVI.06743-11.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol. 2010;84(18):9318. doi:10.1128/JVI.01049-10.
   PubMed Web of Science ®Google Scholar
• Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, Gao GF. T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV. Antivir Res. 2017;137:82. doi:10.1016/j.antiviral.2016.11.006.
   PubMed Web of Science ®Google Scholar
• Bonifacius A, Tischer-Zimmermann S, Dragon AC, Gussarow D, Vogel A, Krettek U, Gödecke N, Yilmaz M, Kraft ARM, Hoeper MM, et al. COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity. 2021;54(2):340. doi:10.1016/j.immuni.2021.01.008.
   PubMed Web of Science ®Google Scholar
• Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate, Wu JE, Alanio C, Kuri-Cervantes L, Pampena MB, D’Andrea K, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;369(6508). doi:10.1126/science.abc8511.
   PubMed Web of Science ®Google Scholar
• Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. Resp Res. 2020;21(1):74. doi:10.1186/s12931-020-01338-8.
   PubMed Web of Science ®Google Scholar
• Zhang X, Cai H, Hu J, Lian J, Gu J, Zhang S, Ye C, Lu, Jin C, Yu G, et al. Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. Int J Infect Dis. 2020;94:81. doi:10.1016/j.ijid.2020.03.040.
   PubMed Web of Science ®Google Scholar
• Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, Song S, Ma Z, Mo P, Zhang Y, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020;221(11):1762. doi:10.1093/infdis/jiaa150.
   PubMed Web of Science ®Google Scholar
• Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, Meece J, Olsho LEW, Caban-Martinez AJ, Fowlkes AL, Lutrick K, et al. Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med. 2021;385(4):320–11. doi:10.1056/NEJMoa2107058.
   PubMed Web of Science ®Google Scholar
• Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, Flaxman A, Wright D, Bellamy D, Bittaye M, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2020;27:270–78. doi:10.1038/s41591-020-01194-5
   Google Scholar
• Alter G, Yu J, Liu J, Chandrashekar A, Borducchi EN, Tostanoski LH, McMahan K, Jacob-Dolan C, Martinez DR, Chang A, et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature (London). 2021;596(7871):268–72. doi:10.1038/s41586-021-03681-2.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Gagne M, Wagner DA, O' Connell S, Narpala SR, Flebbe DR, Andrew SF, Davis RL, Flynn B, Johnston TS, et al. Protection against SARS-CoV-2 beta variant in mRNA-1273 vaccine-boosted nonhuman primates. Science. 202174(6573):1343–53. doi: 10.1126/science.abl8912.
   Google Scholar
• Sanchez-Felipe L,Vercruysse T, Sharma S, Ma J, Lemmens V, Van Looveren D, Arkalagud Javarappa MP, Boudewijns R, Malengier-Devlies B, Liesenborghs L, et al. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Nature. 2020;590(7845):320–25. doi:10.1038/s41586-020-3035-9.
   PubMed Web of Science ®Google Scholar
• Sun W, McCroskery S, Liu W-C, Leist S, Liu Y, Albrecht R, Slamanig S, Oliva J, Amanat F, Schaefer A, et al. A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine. bioRxiv. 2020. doi:10.1101/2020.07.30.229120.
   Google Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Lederer K, Castaño D, Gómez Atria D, Oguin TH, Wang S, Manzoni TB, Muramatsu H, Hogan MJ, Amanat F, Cherubin P, et al. SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation. Immunity. 2020;53(6):1281. doi:10.1016/j.immuni.2020.11.009.
   PubMed Web of Science ®Google Scholar